1. World Health Organization. Global action plan on the public health response to dementia 2017-2025. Geneva, Switzerland: World Health Organization; 2017.
2. Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D, et al. Dementia prevention, intervention, and care. Lancet 2017;390:2673–734.
3. Forette F, Seux ML, Staessen JA, Thijs L, Babarskiene MR, Babeanu S, et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 2002;162:2046–52.
4. Scheinberg P. Dementia due to vascular disease: a multifactorial disorder. Stroke 1988;19:1291–9.
5. Duron E, Hanon O. Hypertension, cognitive decline and dementia. Arch Cardiovasc Dis 2008;101:181–9.
6. van Dijk EJ, Breteler MM, Schmidt R, Berger K, Nilsson LG, Oudkerk M, et al. The association between blood pressure, hypertension, and cerebral white matter lesions: cardiovascular determinants of dementia study. Hypertension 2004;44:625–30.
7. Faraco G, Iadecola C. Hypertension: a harbinger of stroke and dementia. Hypertension 2013;62:810–7.
8. Craft S. The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged. Arch Neurol 2009;66:300–5.
9. de la Torre JC. Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol 2004;3:184–90.
10. Meyer JS, Rauch G, Rauch RA, Haque A. Risk factors for cerebral hypoperfusion, mild cognitive impairment, and dementia. Neurobiol Aging 2000;21:161–9.
11. Skoog I, Gustafson D. Hypertension and related factors in the etiology of Alzheimer's disease. Ann N Y Acad Sci 2002;977:29–36.
12. Breteler MM. Vascular involvement in cognitive decline and dementia: epidemiologic evidence from the Rotterdam Study and the Rotterdam Scan Study. Ann N Y Acad Sci 2000;903:457–65.
13. Johnson KA, Albert MS. Perfusion abnormalities in prodromal AD. Neurobiol Aging 2000;21:289–92.
14. Zhao WQ, Townsend M. Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease. Biochim Biophys Acta 2009;1792:482–96.
17. Jimenez-Balado J, Riba-Llena I, Abril O, Garde E, Penalba A, Ostos E, et al. Cognitive impact of cerebral small vessel disease changes in patients with hypertension. Hypertension 2019;73:342–9.
18. Spence JD. Preventing dementia by treating hypertension and preventing stroke. Hypertension 2004;44:20–1.
20. Peila R, White LR, Masaki K, Petrovitch H, Launer LJ. Reducing the risk of dementia: efficacy of long-term treatment of hypertension. Strok 2006;37:1165–70.
21. Forette F, Seux ML, Staessen JA, Thijs L, Birkenhager WH, Babarskiene MR, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998;352:1347–51.
23. Applegate WB, Pressel S, Wittes J, Luhr J, Shekelle RB, Camel GH, et al. Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the systolic hypertension in the elderly program. Arch Intern Med 1994;154:2154–60.
24. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003;21:875–86.